New Chemo-Free combo shows promise for colorectal cancer
NCT ID NCT07398326
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase II trial tests a combination of two drugs, anlotinib and sintilimab, as a first treatment for advanced colorectal cancer that has spread but not to the liver. The goal is to shrink tumors and control the disease without using standard chemotherapy. About 37 patients who cannot or prefer not to have chemo will take part at one hospital in China.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
anlotinib and sintilimab
What this could lead to
If successful, this could offer a chemotherapy-free treatment option for certain colorectal cancer patients, potentially improving outcomes with fewer side effects.
What could go wrong
This is a small Phase II trial with only 37 participants, so results may not apply broadly. The combination may cause side effects or fail to outperform standard treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Second Affiliated Hospital of Naval Medical University
RECRUITINGShanghai, 200003, China
Contact Phone: •••-•••-•••• Email: •••••@•••••